Yesterday, SPRC received a
Last month, SPRC uplisted on the NASDAQ exchange bringing a full pipeline of clinical trials scheduled for its proprietary drug candidates. The
SPRC stock traded above average volume, and the price was up after-market following the announcement of the previously mentioned
This represents the fourth patent SPRC has been awarded in the
SPRC's proprietary compounds and therapies including the latest patent are primarily targeted for treating disorders of the central nervous system. These include Tourette Syndrome, Sleep Apnea, Autism Spectrum Disorder, Pain and Epilepsy.
The aforementioned conditions comprise a nearly
In a private placement last year, SPRC raised
SPRC is a clinical stage biotechnology pharmaceutical company. The company specializes in CBD-based therapies and is on pace for a busy year according to their clinical trial schedule.
Drug Candidates Set Schedule For Clinical Trials
The Company is currently engaged in drug development programs for its portfolio of technologies and assets based on cannabinoid pharmaceuticals. Its drug candidates are:
SCI-110 for the treatment of Tourette Syndrome (TS) and Obstructive Sleep Apnea
SCI-160 for the treatment of pain
SCI-210 for the treatment of Epilepsy and Autism Spectrum Disorder (ASD)
For its leading drug candidate, SCI-110, SPRC already has supply chain infrastructure for the manufacturing and delivery of the drug.
SPRC Receives Patents In
Adi Zuloff-Shani, PhD, and CTO of SPRC, says, "As an innovative pharmaceutical company, our IP portfolio is one of our greatest and most important assets. Obtaining a
"We are pleased that the
"Our growing portfolio of patents is a testament to the dedication and innovation of the
It applies unique technologies through non-psychoactive cannabinoid pharmaceuticals.
Clinical Trial Outline:
The Company is making preparations for its SCI-110 IIb clinical trials for Tourette Syndrome. They will be conducted with the
SPRC is preparing for Phase IIA clinical trials of SCI-110 for patients with AD and Agitation. They will be conducted with the approval of the
Clinical trials will also be conducted by agreement with the
Pre-clinical studies will begin for evaluation of drug SCI-210 at
SPRC received necessary approvals from the Israeli Medical Cannabis Unit (IMCA) and the Ethical Committee.
SCI-160 tested positively for the treatment of neuropathic and post-operative pain. The controlled pre-clinical trial was conducted at the
For more information, contact IR@scisparc.com
With all of these potential catalysts on the horizon, keep SPRC stock on your
Disclaimers: TopNewsGuide 'TNG', a Razor Pitch publication, is responsible for the production and distribution of this content. TNG is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by TNG is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall TNG. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by TNG., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. TNG. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
CONTACT:
mark@razorpitch.com
(754) 233-0966
.
(C) 2022 M2 COMMUNICATIONS, source